Stealth Bio posts plans for $86M IPO; Sanofi out-licenses drug for neuroendocrine-related disease

→ Newton, MA-based Stealth BioTherapeutics joined the queue of biotechs looking to jump into Nasdaq in early 2019. The company is focused on mitochondrial dysfunction, listing plans to raise $86 million. Morningside Venture controls 95.3% of the equity.

→ Little Acer Therapeutics $ACER has in-licensed a non-peptide tachykinin NK3 receptor drug called osanetant from Sanofi with plans to develop it for neuroendocrine-related disorders. Acer CEO Chris Schelling touted the drug’s “robust non-clinical, pharmacokinetic and human safety data.”

Ling Zhang is headed back to JPMorgan Chase to head up their healthcare and tech investing group in China, according to a report in Reuters. Zhang left JPMorgan three years ago to join BGI Genomics as COO.

→ Boston-based Life Biosciences LLC has inked a deal to invest up to $31.4 million into Prana Biotechnology $PRAN.

Deciphera $DCPH says it’s expanding a Phase I study of DCC-3014, an investigational small molecule switch control inhibitor of CSF1R, after registering some positive results as well as dose-limiting toxicity. Researchers plan to add patients with Tenosynovial Giant Cell Tumors. The stock edged down in early trading Wednesday.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->